Liquidia Technologies

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.

Liquidia Technologies headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma, Therapeutics, Nanotechnology sector. The company focuses on Biotechnology and has secured $158.0B in funding across 380 round(s). With a team of 101-250 employees, Liquidia Technologies is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Liquidia Technologies, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.